Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 30, 2022 at 04:49 am IST
Share
Shanghai Haohai Biological Technology Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 473.62 million compared to CNY 382.59 million a year ago. Revenue was CNY 473.62 million compared to CNY 382.59 million a year ago. Net income was CNY 60.94 million compared to CNY 96.99 million a year ago. Basic earnings per share from continuing operations was CNY 0.35 compared to CNY 0.55 a year ago. Diluted earnings per share from continuing operations was CNY 0.35 compared to CNY 0.55 a year ago.
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.